Last checked at 24 Mar 2022 11:32
24 March 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Result of Annual General Meeting
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. The results of the proxy voting for the AGM are set out below.
Resolution (*Special Resolution) | Total Shares Voted | Shares | % | ||
For | Against | For | Against | ||
1. To receive the annual report and audited accounts for the year ended 31 December 2021 | 20,171,351
| 20,171,151
| 200
| 99.999
| 0.001
|
2. To re-elect Nigel Theobald as a Director of the Company | 20,195,551
| 20,026,641
| 168,910
| 99.164
| 0.836
|
3. To re-elect David Templeton as a Director of the Company | 20,195,551
| 20,016,641
| 178,910
| 99.114
| 0.886
|
4. To re-appoint Saffery Champness LLP as auditor to the company and authorise the directors to determine their remuneration | 20,193,244
| 19,930,222
| 263,022
| 98.697
| 1.303
|
5. To authorise the Directors to allot shares | 20,192,844
| 19,694,856
| 497,988
| 97.534
| 2.466
|
6*. To disapply pre-emption rights | 20,190,444
| 19,928,374
| 262,070
| 98.702
| 1.298
|
Enquiries:
N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director | Via IFC Advisory |
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker
| Tel: +44 (0)20 3657 0050 |
IFC Advisory Limited Financial PR Graham Herring Zach Cohen | Tel: +44 (0)20 3934 6630 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.